9 March 2023
SkinBioTherapeutics plc
("SBTX" or the "Company")
Director Bed & ISA Dealings
SkinBioTherapeutics plc (AIM: SBTX), the life science company focused on skin health, announces that it received notification on 9 March 2023 that Stuart Ashman, CEO and PDMR, sold 89,472 ordinary shares of 1p each in the Company ("Ordinary Shares") and repurchased 86,387 Ordinary Shares into Mr Ashman's ISA account. Following this transaction Stuart Ashman's beneficial interest in the Company shares has decreased from 281,250 to 278,165 ordinary shares, with the variance owing to commissions and costs of the transactions.
Details of PDMR transaction
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Stuart Ashman | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | PDMR (CEO) | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | SkinBioTherapeutics plc | |||
| b) | LEI | 213800YMQOCB23FX6I06 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares in SkinBioTherapeutics plc | |||
| | | ||||
| Identification code | GB00BF33H870 | ||||
| | | ||||
| b) | Nature of the transaction | Sale and purchase of ordinary shares | |||
| c) | Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | Sale at 22.75 p | 89,472 | | |
| | | Purchase at 22.75 p | 86,387 | | |
| | | | | | |
| d) | Aggregated information | | |||
| | | ||||
| - Aggregated volume | n/a | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e) | Date of the transactions | 6 March 2023 | |||
| f) | Place of the transaction | N/A | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
